SONIC HEALTHCARE LIMITED (SHL)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

SHL

SHL - SONIC HEALTHCARE LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 3.24
Index: ASX50 | ASX100 | ASX200 | ASX300 | ALL-ORDS

Sonic Healthcare is one of the world's largest medical diagnostics companies, providing laboratory and imaging services to medical practitioners, hospitals, community health services, and their collective patients. It was first listed in 1987.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$21.20

13 Mar
2026

0.090

OPEN

$21.12

0.43%

HIGH

$21.33

1,218,007

LOW

$20.95

TARGET
$25.313

-0.10 change from previous day

 19.4% upside
Franking for last dividend paid out: 60%
OTHER COMPANIES IN THE SAME SECTOR
ACL . ALC . BMT . DOC . EBO . HLS . IDX . M7T . MPL . MVF . NHF . RHC .
FNARENA'S MARKET CONSENSUS FORECASTS
SHL: 1
Title FY24
Actual		 FY25
Actual		 FY26
Forecast		 FY27
Forecast
EPS (cps) xxx 107.0 124.1 xxx
DPS (cps) xxx 107.0 105.5 xxx
EPS Growth xxx - 0.4% 16.1% xxx
DPS Growth xxx 0.9% - 1.4% xxx
PE Ratio xxx N/A 16.9 xxx
Dividend Yield xxx N/A 5.0% xxx
Div Pay Ratio(%) xxx 100.0% 85.0% xxx

Dividend yield today if purchased 3 years ago: 3.16%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 5.11

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 03/09 - ex-div 63.00c (franking 35%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx107.0
DPS All xxxxxxxxxxxxxxx107.0
Sales/Revenue xxxxxxxxxxxxxxx9,489.5 M
Book Value Per Share xxxxxxxxxxxxxxx1,733.3
Net Operating Cash Flow xxxxxxxxxxxxxxx1,296.8 M
Net Profit Margin xxxxxxxxxxxxxxx5.41 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx6.32 %
Return on Invested Capital xxxxxxxxxxxxxxx4.14 %
Return on Assets xxxxxxxxxxxxxxx3.21 %
Return on Equity xxxxxxxxxxxxxxx6.32 %
Return on Total Capital xxxxxxxxxxxxxxx5.95 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx446.5 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx461 M
Long Term Debt xxxxxxxxxxxxxxx4,710 M
Total Debt xxxxxxxxxxxxxxx5,171 M
Goodwill - Gross xxxxxxxxxxxxxxx9,315 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx674 M
Price To Book Value xxxxxxxxxxxxxxx1.55

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx462.7 M
Capex % of Sales xxxxxxxxxxxxxxx4.88 %
Cost of Goods Sold xxxxxxxxxxxxxxx7,072 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx1,637 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx231 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.3

No. Of Recommendations

7
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

UBS

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgan Stanley

xx/xx/xxxx

3

xxxxx-xxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

23/02/2026

1

Upgrade to Outperform from Neutral

$27.50

29.72%

Sonic Healthcare's 1H26 revenue beat was pulled down by softer margins, Macquarie notes, leading earnings to be in line with expectations. FY26 guidance is maintained, with the broker at the midpoint.

The performance of recent EU acquisitions was ahead of Macquarie's forecasts, while the Australian business outperformed peers due to Sonic's specialist skew and private billing.

Early European synergies are now visible, while the full uplift lays ahead, supported by resilient Australian trends and the US drag easing, thus strengthening medium-term earnings trajectory, Macquarie suggests.

Upgrade to Outperform from Neutral. Target rises to $27.50 from $25.20.

FORECAST
Macquarie forecasts a full year FY26 dividend of 104.00 cents and EPS of 127.00 cents.
Macquarie forecasts a full year FY27 dividend of 100.00 cents and EPS of 134.00 cents.

Citi

xx/xx/xxxx

5

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Bell Potter

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Jarden

03/03/2026

3

Neutral

$21.90

3.30%

Jarden notes Healthcare's 1H26 net proft after tax beat of 3.8% was largely due because of lower-than-guided depreciation following changes to LADR lease accounting, while revenue was 2.2% ahead of consensus but EBITDA margin missed by -50bps.

FY26 constant currency earnings (EBITDA) guidance of $1.87bn–$1.95bn was maintained, although a $37m FX tailwind in 1H is expected to reverse to an estimated -$30m headwind in 2H at current spot rates.

The US business recorded 0% organic growth following the loss of the Alabama payor contract, with further restructuring costs expected and the previously anticipated US$20–25m revenue collection benefit removed from forecasts.

Underlying diluted EPS forecasts are cut by -7.4%, -15.1% and -17.5% across FY26–FY28, reflecting weaker revenue, margin pressure and spot FX assumptions.

Neutral retained and target price reduced to $21.90 from $26.27.

FORECAST
Jarden forecasts a full year FY26 dividend of 108.00 cents and EPS of 116.30 cents.
Jarden forecasts a full year FY27 dividend of 110.00 cents and EPS of 121.60 cents.
Access Extra Coverage Research History >

SHL STOCK CHART

FNArena News on SHL

1
Rudi’s View: Post-February Conviction Calls

Mar 12 2026 - Rudi's View
2
Australian Broker Call *Extra* Edition – Mar 12, 2026

Mar 12 2026 - Daily Market Reports
3
Rudi’s View: TACO Time?

Mar 11 2026 - Rudi's View
4
Rudi’s View: A Season Of Large Cap Winners

Mar 04 2026 - Rudi's View
5
Australian Broker Call *Extra* Edition – Mar 03, 2026

Mar 03 2026 - Daily Market Reports

Latest Healthcare services News

1
Better Times Ahead For Sonic Healthcare?

Jun 20 2025 - Australia
2
The Significance Of Cosmetique’s ASX Listing

Feb 26 2025 - Small Caps
3
Building The No 3 Diagnostic Imaging Player

Jun 19 2024 - Small Caps
4
Capitol Health’s Higher Margin Outlook

Mar 13 2024 - Small Caps
5
Treasure Chest: Ramsay Health Care

Oct 26 2023 - Treasure Chest
6
Timing Seems Right For Alcidion Group

Jun 21 2023 - Small Caps
7
No Enthusiasm To Combine ACL & Healius

Mar 21 2023 - Australia
8
Dr Boreham’s Crucible: Alcidion

Dec 13 2022 - Small Caps
9
No Straight Covid-Relief For Ramsay Health Care

Nov 15 2022 - Australia
10
Dr Boreham’s Crucible: Mach7 Technologies

Nov 14 2022 - Small Caps